摘要
目的比较不同剂量泮托拉唑治疗慢性阻塞性肺疾病急性加重(AECOPD)患者的临床疗效。方法选取2015年1月—2017年5月涿州市医院呼吸重症监护室(RICU)收治的AECOPD患者152例,根据随机、单盲、对照原则并采用信封法分为对照组50例、小剂量组51例和大剂量组51例。对照组患者给予常规治疗,小剂量组患者在常规治疗基础上给予小剂量泮托拉唑(40 mg/次,1次/d),大剂量组患者在常规治疗基础上给予大剂量泮托拉唑(40 mg/次,2次/d);3组患者均连续治疗15 d。比较3组患者临床疗效、院内感染发生情况及转出RICU时间,并观察3组患者治疗期间不良反应发生情况。结果 (1)3组患者临床疗效比较,差异无统计学意义(P>0.05)。(2)3组患者院内感染发生率比较,差异无统计学意义(P>0.05);小剂量组、大剂量组患者转出RICU时间短于对照组(P<0.05),而小剂量组、大剂量组患者转出RICU时间比较,差异无统计学意义(P>0.05)。(3)治疗期间,3组患者其他原因所致死亡发生率比较,差异无统计学意义(P>0.05)。小剂量组患者上腹痛、腹胀发生率低于对照组(P<0.05),而小剂量组与对照组患者反酸、出血、消化道出血所致死亡发生率比较,差异无统计学意义(P>0.05);大剂量组患者上腹痛、腹胀、反酸、出血、消化道出血所致死亡发生率低于对照组(P<0.05);大剂量组与小剂量组患者上腹痛、腹胀、反酸、出血、消化道出血所致发生率比较,差异无统计学意义(P>0.05)。结论小剂量(40 mg/次,1次/d)与大剂量(40 mg/次,2次/d)泮托拉唑治疗AECOPD患者的临床疗效相当,有利于缩短转出RICU时间且不增加院内感染发生风险、安全性较高,临床应根据患者病情酌情调整泮托拉唑剂量。
Objective To compare the clinical effect of different doses of pantoprazole on acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods From January2015to May2017,a total of152patients with AECOPD were selected in Respiratory Intensive Care Unit(RICU),Zhuozhou Hospital,and they were divided into control group(n=50),low-dose group(n=51)and high-dose group(n=52)according to random,single-blind,control principle and envelope method.Patients in control group received conventional treatment,patients in low-dose group received low dose of pantoprazole(40mg per time,1time per day),while patients in high-dose group received high dose of pantoprazole(40mg per time,2times per day);all of the three groups continuously treated for15days.Clinical effect,incidence of hospital-acquired infection and shifting time from RICU were compared in the three groups,and incidence of adverse reactions was observed during treatment.Results(1)No statistically significant differences of clinical effect was found in the three groups(P>0.05).(2)No statistically significant differences of incidence of hospital-acquired infection was found in the three groups(P>0.05);shifting time from RICU in low-dose group and high-dose group were statistically significantly lower than those in control group,respectively(P<0.05),while no statistically significant differences of shifting time from RICU was found between low-dose group and high-dose group(P>0.05).(3)No statistically significant differences of incidence of death due to other causes was found in the three groups during treatment(P>0.05).Incidence of stomachache and abdominal distension in low-dose group was statistically significantly lower than that in control group,respectively(P<0.05),while no statistically significant differences of incidence of sour regurgitation,bleeding,death due to gastrointestinal bleeding were found between control group and low-dose group(P>0.05);incidence of stomachache,abdominal distension,sour regurgitation,bleeding and death due to gastrointestinal bleedi ng in high-dose group were statistically significantly lower than those in control group,respectively(P<0.05);no statistically significant differences of incidence of stomachache,abdominal distension,sour regurgitation,bleeding or death due to gastrointestinal bleeding was found between low-dose group and highdose group(P>0.05).Conclusion Low dose of pantoprazole(40mg per time,1time per day)has similar clinical effect with high dose of pantoprazole(40mg per time,2times per day)in treating AECOPD,is helpful to shorten the shifting time from RICU,without increasing risk of hospital-acquired infection,and is relativity safe,so we should adjust the dose of pantoprazole according to the condition of patients on clinic.
作者
张占强
吴春艳
王美玲
牛慧艳
方彬
ZHANG Zhan-qiang;WU Chun-yan;WANG Mei-ling;NIU Hui-yan;FANG Bin(Department of Respiratory Medicine,Zhuozhou Hospital,Zhuozhou 072750,China;Department of Respiratory Medicine,the First Central Hospital of Baoding,Baoding 071000,China;Department of Neurology,Zhuozhou Hospital,Zhuozhou 072750,China)
出处
《实用心脑肺血管病杂志》
2018年第10期70-73,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金
保定市科学计划与发展指导计划项目(15ZF058)
关键词
肺疾病
慢性阻塞性
急性加重
泮托拉唑
疗效比较研究
Pulmonary disease,chronic obstructive
Acute exacerbation
Pantoprazole
Comparative effectiveness research